General Mills and Protalix Miss Estimates as Market Eyes FY26 Guidance

The mid-March earnings window has delivered a sobering reality check for two very different corners of the market: consumer staples and specialized biotechnology. General Mills and Protalix BioTherapeutics both issued reports on March 18, 2026, that failed to meet Wall Street’s top-line and bottom-line expectations. While the misses suggest immediate operational headwinds, the decision by both management teams to maintain or provide optimistic fiscal year 2026 (FY26) guidance indicates a belief that the current turbulence is transitory rather than structural.

For General Mills, the miss highlights the ongoing struggle within the packaged foods industry to balance price increases with consumer volume. As inflation remains a persistent shadow over household budgets, even established brands in the cereal and snack categories are seeing price elasticity take a toll. The 'top-line miss' typically points to lower-than-expected sales volume or a shift in consumer preference toward private-label alternatives. However, the company’s decision to reaffirm its FY26 outlook suggests that its 'Accelerate' strategy—which focuses on brand building, innovation, and portfolio reshaping—is expected to yield results in the latter half of the year. Investors will likely scrutinize the company's ability to manage input costs and supply chain efficiencies to protect margins if volume growth remains sluggish.

“

General Mills and Protalix BioTherapeutics both issued reports on March 18, 2026, that failed to meet Wall Street’s top-line and bottom-line expectations.

Protalix BioTherapeutics, a much smaller player in the orphan drug space, faced a similar double-miss. In the biotech sector, revenue misses are frequently tied to the timing of milestone payments or slower-than-anticipated commercial uptake of newly approved therapies. For Protalix, which is heavily focused on its ProCellEx protein expression system and its treatment for Fabry disease, the quarterly results reflect the high-stakes nature of commercializing specialized biologics. The fact that Protalix provided a clear FY26 outlook alongside the miss is a strategic move to reassure investors of its cash runway and the long-term potential of its partnership with Chiesi Global Rare Diseases. For a company at this stage, the narrative often shifts quickly from current quarterly losses to the 'peak sales' potential of its lead assets.